| Document |
Document Title |
|
WO/2017/139414A1 |
The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating a disease associated with IDO, for example, cancer or an infectious disease (e.g., viral or bacterial infectious diseases)...
|
|
WO/2017/132023A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, compositions containing suc...
|
|
WO/2017/070482A3 |
PPSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed.
|
|
WO/2017/099232A1 |
[Problem] To provide a novel gelling agent containing a mono-urea derivative. [Solution] A gelling agent comprising a compound represented by formula [1] (in the formula, R1 represents a C2-20 straight chain or branched chain alkyl group...
|
|
WO/2017/095969A1 |
The present invention provides hTERT modulators and methods for producing and using the same. In particular, the present invention provide a compound of the formula as described herein. Some aspects of the invention are based on the char...
|
|
WO/2017/070482A2 |
PPSMA binding scaffolds with radioiodinated, radiobrominated and radioastatinated labeled prosthetic groups are disclosed. Pharmaceutical compositions and methods of treating PSMA expressing cells or tumors also are disclosed.
|
|
WO/2017/063091A1 |
The present disclosure relates to a compound that has biocidal activity or is a precursor of a compound with biocidal activity. The compound comprises an N-halamine precursor, at least one quaternary ammonium and at least one coating-inc...
|
|
WO/2017/062856A1 |
A synergistic agricultural formula including at least one diacyl or diaryl urea, such as a Ν,Ν'-diformylurea, and at least metal complex, such as metal complexes of cobalt, nickel, silver or other metals, is applied to plants at physio...
|
|
WO/2017/011767A3 |
The present invention relates to certain pyrazole derivatives of Formula (I) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor and their uses for the treatment and prophylaxis of visual h...
|
|
WO/2017/055552A1 |
The invention relates to the field of polyisocyanate compositions for the production of coatings and adhesives. The composition according to the invention combines a polyisocyanate compound with biuret motifs, a protic, polar reactive di...
|
|
WO/2017/056832A1 |
Provided is an active-light-sensitive or radiation-sensitive composition that contains (A) a compound having two or more of the structures represented by general formula (1), the compound not having an acid crosslinking group, and (B) a ...
|
|
WO/2017/047572A1 |
A heat-sensitive recording material obtained by forming a heat-sensitive recording layer, which contains a basic dye and a developer, on a supporting body. The developer is composed of at least one N-substituted amino acid derivative rep...
|
|
WO/2017/044314A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2017/043390A1 |
The present invention provides a method and a device capable of producing urea more efficiently. In the present invention, prior to removing unreacted materials from a urea synthesis solution obtained from a stripper, the pressure of the...
|
|
WO/2017/043391A1 |
The present invention provides a urea production method and production device, capable of increasing the rate of conversion into urea and decreasing the amount of steam consumed. In the present invention, the reactor temperature is raise...
|
|
WO/2017/040191A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2017/036405A1 |
A compound having a chemical structure of formula I, wherein n is 0 or 1, X is N or C-R1, R1 is H or Cl, R2 and R3 are independently H, a halogen or an alkyl group, Ar is a substituted or unsubstituted phenylene or naphthylene group, wit...
|
|
WO/2017/038871A1 |
The purpose of the present invention is to provide a compound having inhibitory activity with respect to the discoidin domain receptor 1. The present invention provides a urea derivative represented by the formula below or a pharmacologi...
|
|
WO/2017/040194A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2017/038873A1 |
The purpose of the present invention is to provide a compound having inhibitory activity with respect to the discoidin domain receptor 1. The present invention provides a urea derivative represented by the formula below or a pharmacologi...
|
|
WO/2017/031156A1 |
Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymph...
|
|
WO/2017/023907A1 |
The present disclosure relates to phenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor (FPR), such as agonism o...
|
|
WO/2017/017036A1 |
The present invention relates to ureaurethanes of the following formula (1) in which at least one of the R1 or R2 radicals is a mono- or polyunsaturated, branched or unbranched alkenyl or alkynyl radical having 12 to 24 carbon atoms, n i...
|
|
WO/2017/016523A1 |
The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical co...
|
|
WO/2017/013265A1 |
The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs).The present invention further ...
|
|
WO/2016/210414A1 |
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...
|
|
WO/2016/207726A1 |
The present description provides oligourea catalysts, a polar helical oligomeric strands, and methods for catalyzing reactions with polar helical oligomeric strands and oligourea catalysts. In particular, the invention relates to a polar...
|
|
WO/2016/189877A1 |
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...
|
|
WO/2016/153354A9 |
Disclosed is a method for the integrated production of two different urea products. One is an aqueous urea solution suitable for use in NOx abatement (generally indicated as Diesel Exhaust Fluid – DEF). The other is a solution used as ...
|
|
WO/2016/172425A1 |
Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. Formula I is exemplified below: Formula (i)
|
|
WO/2016/168769A1 |
Disclosed herein are switches for regulating the activity of a chimeric antigen receptor effector cells (CAR-ECs). The switches generally comprise a chimeric antigen receptor-interacting domain (CAR-ID) and a target interacting domain TI...
|
|
WO/2016/161286A1 |
There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, suc...
|
|
WO/2016/126596A3 |
Graphene-based materials for sequestering urea from aqueous solutions are provided. The graphene-based materials include graphene aggregates as well as graphene oxides.
|
|
WO/2016/159336A1 |
The present invention is a urea production method characterized by comprising a first concentration step that concentrates an aqueous urea solution, a granulating step that produces solid urea from a concentrated aqueous urea solution ge...
|
|
WO/2016/156015A1 |
Process and respective reactor for urea or melamine synthesis, comprising sonication treatment of at least part of a reaction liquid mass or two-phase mixture contained inside said reactor.
|
|
WO/2016/153354A1 |
Disclosed is a method for the integrated production of two different urea products. One is an aqueous urea solution suitable for use in NOx abatement (generally indicated as Diesel Exhaust Fluid – DEF). The other is a solution used as ...
|
|
WO/2016/149099A1 |
The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.
|
|
WO/2016/127085A1 |
Novel diphenylurea and benzylbenzenesulfonamide compounds are disclosed along with methods of inhibiting the activity of TRPV1 and methods of treating pain associated with transient receptor potential vanilloid type 1 (TRPV1) using such ...
|
|
WO/2016/114670A1 |
The invention pertains to the synthesis of carbamate and urea compounds. In particular the invention is directed to the synthesis of carbamate and urea compounds which may be used in the production of compounds that are used to stabilize...
|
|
WO/2016/101885A1 |
The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The ...
|
|
WO/2016/093562A1 |
The present invention relates to an ionic catalyst comprising a nitrogen-containing organic cation chemically immobilized to a polymer resin carrier and an anion thereof, and a method for selectively preparing N,N'-substituted urea by re...
|
|
WO/2015/151081A3 |
Provided are linkers containing hydrazine used for the specific conjugation of compounds/cytotoxic agents to a cell-binding molecule, through bridge linking a pair of thiols on the cell-binding molecule, methods of making such linkers, a...
|
|
WO/2016/071347A1 |
The invention relates to novel carbodiimides comprising terminal urea and/or urethane groups of formula (I), in which R can be identical or different and is selected from the group of -NHCONHRI-, -NHCONR'RII- and -NHCOORIII- groups, wher...
|
|
WO/2016/063990A1 |
The present invention relates to a compound represented by general formula (1). (The definition of each group in the formula is as described in the specification.) The compound is useful as a prophylactic and/or therapeutic agent for KCN...
|
|
WO/2016/062585A1 |
The present invention relates to a compound of formula (I) wherein: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are as defined herein; and wherein the compound of formula (I) is optionally present as an agrochemically acce...
|
|
WO/2016/052953A1 |
The present specification relates to a (meth)acrylate compound, and a copolymer and a homopolymer comprising a repeating unit derived from the compound.
|
|
WO/2016/052592A1 |
This heat-sensitive recording material is configured to contain, as a color-developing compound, at least one compound represented by one of formulae (1)-(3).
|
|
WO/2016/049774A1 |
Urea-based and bis-urea based compounds and analogues thereof are disclosed. These compounds are useful in the treatment of androgen-dependent diseases or disorders and androgen receptor-mediated diseases or disorders. Specifically, the ...
|
|
WO/2016/049518A1 |
A novel solid drug form of N-(2,6-bis(1-methylethyl)phenyl)-N'-((1-(4-(dimethylamino)ph
enyl)cyclopentyl)methyl)urea hydrochloride (also referred to "ATR-101") suitable for oral dosing, and to compositions, methods and kits relating ther...
|
|
WO/2016/047356A1 |
The present invention relates to a process for producing a high-purity aqueous urea solution while utilizing a urea production process at least including a urea synthesis step in which urea is synthesized from feed materials to produce a...
|
